Shire

Banks, oils push European shares to 2-week low

By Atul Prakash LONDON, Nov 20 (Reuters) - European equities slipped for a fourth session on Friday to a two-week closing low as financials lost ground on concerns over some banks' exposure to Ukrainian debt, while weaker crude...

powered by

Banks, commods weigh on FTSE, down for 4th session

20 Nov, 2009 @ 07:45 am ET | written by Reuters Britain's top share index was lower at midday on Friday, with gains in defensive pharmaceutical stocks and food producers outweighed by weakness in banks and energy stocks. By...

powered by

Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research...

67 WALL STREET, New York - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. Traditional Chinese Medicine VS. Western...

powered by

FTSE up 0.6 pct; Commodities, banks lead rebound

Britain's top share index rose 0.6 percent in early trade on Friday as commodity and banking stocks led a broad-based rally. By 0900 GMT, the FTSE 100 was up 30.65 points at 5298.35 after closing down 74.43 points at 5267.70 on...

powered by

Rock chick Hayley's Idol attitude

Who will win? ... Australian Idol finalists Hayley Warner, 17 and Stan Walker, 18 / Pic: Justin Lloyd Source: The Daily Telegraph HAYLEY Warner likes to wear the pants. "How long is this going to be because I've got a friend...

powered by

This Stock Is a Train Wreck (at Motley Fool)

The problem with a train wreck isn't the first car that goes off the track, but all the ones farther back that come crashing along behind it. Then the first car slid off the track, as the Food and Drug Administration announced...

powered by

Refocusing on Therapeutic Protein Production in Plants

SREPORT Patricia F. Dimond, Ph.D. In July FDA asked Shire and Protalix BioTherapeutics to submit treatment protocols for their Gaucher disease therapies in the wake of Genzyme’s Allston Landing plant closing. The closing thus...

powered by

Genzyme's Problems Continue (Zacks.com)

problems continue with the company recently announcing the discontinuation of the development of its kidney disease drug. Genzyme reported results on its advanced phosphate binder (APB) from a phase II/III study. Although the...

powered by

Intralinks Survey: Life Sciences Deal Activity Will Increase in 2010

NEW YORK, NY - IntraLinks(R), the leading provider of critical information exchange solutions, today announced the results of a survey of key decision makers attending the BioNetwork West 2009 conference on their anticipated...

powered by

Winter Fundraiser, An Early Start

I'm beginning this site's winter fundraiser a bit earlier than I'd originally planned for a couple of reasons. One, the last few fundraisers have taken longer than the two weeks or so of the glory day of 2007 and 2008,...

powered by
1 2 3 4 5 next »